Last reviewed · How we verify

NCT04775030: CBD-OCC-APP

Methodology for Developing an Occlusal Appliance With CBD Active Carrier

Status unknown Phase 2, PHASE3 Last updated 1 March 2021
What this trial tests

Phase 2, PHASE3 trial testing CBD occlusal appliance in Temporomandibular Disorder in 40 participants. Status unknown.

Timeline
1 January 2021
Primary endpoint
1 January 2022
1 January 2023

Quick facts

Lead sponsorMedical University of Silesia
PhasePhase 2, PHASE3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment40
Start date1 January 2021
Primary completion1 January 2022
Estimated completion1 January 2023
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Silesia

Who can join

18 and older, any sex, with Temporomandibular Disorder or Myofascial Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the efficacy of the occlusal appliance with active cannabidiol (CBD) molecules in TMD patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Temporomandibular Disorder

Currently open trials in the same condition.

Other Medical University of Silesia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04775030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing